AU2002228913A1 - Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer - Google Patents

Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer

Info

Publication number
AU2002228913A1
AU2002228913A1 AU2002228913A AU2891302A AU2002228913A1 AU 2002228913 A1 AU2002228913 A1 AU 2002228913A1 AU 2002228913 A AU2002228913 A AU 2002228913A AU 2891302 A AU2891302 A AU 2891302A AU 2002228913 A1 AU2002228913 A1 AU 2002228913A1
Authority
AU
Australia
Prior art keywords
lyn
inhibitors
treatment
prostate cancer
signal transduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228913A
Inventor
Shmuel Ben-Sasson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Childrens Medical Center Corp
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem, Childrens Medical Center Corp filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU2002228913A1 publication Critical patent/AU2002228913A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Abstract

The present invention concerns methods for the treatment of prostate cancer by the inhibition of Lyn-kinase associated signal transduction. Preferred in accordance with the invention are inhibitors which comprise sequences derived from specific regions of the Lyn-kinase.
AU2002228913A 2000-12-11 2001-12-11 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer Abandoned AU2002228913A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/735,279 US20020019346A1 (en) 1997-05-21 2000-12-11 Treatment of prostate cancer by inhibiting lyn tyrosine kinase
US09/735,279 2000-12-11
PCT/US2001/047444 WO2002047710A2 (en) 2000-12-11 2001-12-11 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
AU2002228913A1 true AU2002228913A1 (en) 2002-06-24

Family

ID=24955113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002228913A Abandoned AU2002228913A1 (en) 2000-12-11 2001-12-11 Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer

Country Status (6)

Country Link
US (3) US20020019346A1 (en)
EP (1) EP1366063B1 (en)
AT (1) ATE423129T1 (en)
AU (1) AU2002228913A1 (en)
DE (1) DE60137721D1 (en)
WO (1) WO2002047710A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
EP1509545B8 (en) * 2002-05-31 2010-10-13 Merck Serono Biodevelopment SAS Homotrimeric extended obg3 globular head and uses thereof
WO2005032595A2 (en) * 2003-04-23 2005-04-14 Georgetown University Methods and compositions for the inhibition of stat5 in prostate cancer cells
AU2006283211B2 (en) * 2005-08-22 2012-06-21 Melior Pharmaceuticals I, Inc. Methods and formulations for modulating Lyn kinase activity and treating related disorders
US20100152215A1 (en) * 2007-02-20 2010-06-17 Melior Pharmaceuticals I, Inc. Methods of identifying activators of lyn kinase
JP2010534668A (en) * 2007-07-23 2010-11-11 メリオール・ディスカヴァリー・インコーポレイテッド Method for activating IRS-1 and AKT
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
JP7182605B2 (en) 2017-04-10 2022-12-02 メリオール・ファーマスーティカルズ・ワン・インコーポレイテッド Compositions comprising a lyn kinase activator and a TRPM8 agonist and their use in the manufacture of medicaments

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131389A1 (en) * 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
US5508383A (en) * 1994-03-09 1996-04-16 Tap Holdings Inc. Cyclic peptide LHRH antagonists
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
CA2322311C (en) * 1998-03-04 2009-10-13 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
US20020151497A1 (en) 2002-10-17
US20020019346A1 (en) 2002-02-14
WO2002047710A2 (en) 2002-06-20
DE60137721D1 (en) 2009-04-02
EP1366063B1 (en) 2009-02-18
ATE423129T1 (en) 2009-03-15
WO2002047710A3 (en) 2003-04-24
EP1366063A2 (en) 2003-12-03
US20080045460A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
MY134783A (en) Rho-kinase inhibitors
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
IL175770A0 (en) Novel use of peptide compounds for treating central neuropathic pain
MXPA06010904A (en) Tricyclic pyrazole kinase inhibitors.
GB0011358D0 (en) Novel use
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
AU2002228913A1 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
TW200605885A (en) Multicyclic lonidamine analogs
WO2004024082A3 (en) Highly specific modulators of gtpases for target validation
YU30003A (en) Inhibition of the growth factor dependency of tumor cells
MXPA03008946A (en) Methods of synthesizing phenol-containing compounds.
CY1111289T1 (en) COMPOSITIONS OF VOLUME INHIBITORS CONTAINING NITROACRIDINE
WO2005056043A3 (en) Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
IL189502A0 (en) Methods and compositions for inhibiting neoplastic cell growth
LT2003075A (en) Inhibitor of monoamine uptake
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
AU2003236701A1 (en) Guanidino phenylalanin compounds used as urokinase inhibitors
MXPA04004757A (en) Use of an ascomycin for the treatment of blepharitis.
WO2002047711A3 (en) Modulators of activity of g-protein-coupled receptor kinases
AU2003282035A1 (en) Modulation of s6 kinase activity for the treatment of obestiy
WO2003004631A3 (en) USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS.
UA49216A (en) Remedy for treating complication following resection of malignant tumors of skin